Abstract: A filament winding apparatus includes a rail extending in a first direction, a core material support device that supports a core material, and a winding device that winds a fiber bundle onto an outer peripheral surface of the core material, the winding device including: a guide unit having an opening through which the core material passes, and guiding the fiber bundle; and a main frame on which the guide unit is mounted; wherein the main frame is movable relative to the core material in the first direction, the main frame is movable in a second direction orthogonal to the first direction, and the main frame is rotatable around a first rotational axis extending in a third direction orthogonal to each of the first direction and the second direction.

Abstract: A filament winding device includes a fiber bundle retainer that temporarily retains fiber bundles. The fiber bundle retainer includes: a reel member including an outer peripheral portion having pins movable in the axial direction relative to the fiber bundles supplied through fiber bundle guides and rotatable about the axis of the liner, the reel member capable of winding the fiber bundles onto the outer peripheral portion; a first cutting unit configured to cut a part of each of the fiber bundles in the circumferential direction, the part being between a part of the fiber bundle wound on the outer peripheral portion and a part of the fiber bundle wound on the liner; and a second cutting unit different from the first cutting unit and configured to cut a part of each of the fiber bundles in the axial direction, the part being wound on the outer peripheral portion.

Abstract: A method for promoting osteogenesis including administering a therapeutically effective amount of collagen and a calcium absorption promoter to a subject.

Abstract: The present invention provides a method of artificially repressing gene expression, which is simpler to design than conventional methods (the RNAi, ribozyme and antisense methods) and which allows for easier confirmation of the effect. A method of inhibiting the translation reaction of a target gene, comprising cutting out a part of the poly(A) tail and/or 3?-terminal sequence of the target mRNA is provided.

Abstract: A pharmaceutical composition for treating cancer or diabetes which contains the following double-stranded RNA (A) or (B): (A) a double-stranded RNA having a sequence represented by SEQ ID NO:2, SEQ ID NO:4 or SEQ ID NO:8. (B) a double-stranded RNA which has a sequence of 20 to 30 nucleotides that is identical to a partial sequence of a gene encoding human plasma membrane-associated sialidase (NEU3) and contains the sequence represented by SEQ ID NO: 2, SEQ ID NO: 4, or SEQ ID NO: 8, and the double-stranded RNA inhibits the expression of a gene encoding human plasma membrane-associated sialidase (NEU3).

Abstract: A pharmaceutical composition for treating cancer or diabetes which contains the following double-stranded RNA (A) or (B): (A) a double-stranded RNA having a sequence represented by SEQ ID NO:2, SEQ ID NO:4 or SEQ ID NO:8. (B) a double-stranded RNA which has a sequence of 20 to 30 nucleotides that is identical to a partial sequence of a gene encoding human plasma membrane-associated sialidase (NEU3) and contains the sequence represented by SEQ ID NO: 2, SEQ ID NO: 4, or SEQ ID NO: 8, and the double-stranded RNA inhibits the expression of a gene encoding human plasma membrane-associated sialidase (NEU3).

Abstract: The present invention provides a method of producing inulin by bringing inulin synthase into contact with sucrose, wherein: (1) the average polymerization degree of inulin is regulated by controlling the sucrose concentration; (2) the average polymerization degree of inulin is regulated by controlling the temperature upon the above contact; and/or (3) at a stage when the above sucrose is consumed by the above inulin synthase and the reaction reaches an equilibrium state, sucrose is additionally added, and the reaction for generating inulin is further continued. Furthermore, the present invention relates to inulin having a predetermined average polymerization degree, which is obtained by the production method.

Abstract: The present invention relates to a novel inulin synthase having a function and a substrate specificity of acting on sucrose to produce inulin, but not acting on kestose, maltose, lactose, trehalose and cellobiose; and a process for producing inulin comprising the step of allowing the synthase, a culture fluid or cultured cells of a microorganism producing the synthase, or a treated product thereof to contact with sucrose to produce inulin.

Abstract: The present invention provides a method of producing inulin by bringing inulin synthase into contact with sucrose, wherein: (1) the average polymerization degree of inulin is regulated by controlling the sucrose concentration; (2) the average polymerization degree of inulin is regulated by controlling the temperature upon the above contact; and/or (3) at a stage when the above sucrose is consumed by the above inulin synthase and the reaction reaches an equilibrium state, sucrose is additionally added, and the reaction for generating inulin is further continued. Furthermore, the present invention relates to inulin having a predetermined average polymerization degree, which is obtained by the production method.

Abstract: The present invention relates to a novel inulin synthase having a function and a substrate specificity of acting on sucrose to produce inulin, but not acting on kestose, maltose, lactose, trehalose and cellobiose; and a process for producing inulin comprising the step of allowing the synthase, a culture fluid or cultured cells of a microorganism producing the synthase, or a treated product thereof to contact with sucrose to produce inulin.

Abstract: The present invention provides a protein defined in the following (A) or (B), and DNA coding for the same: (A) a protein which has the amino acid sequence of SEQ ID NO: 2 or SEQ ID NO: 4, or (B) a protein which has the amino acid sequence including substitution, deletion, insertion, or transition of one or several amino acid residues in SEQ ID NO: 2 or SEQ ID NO: 4, and exhibits activity to eliminate a sialic acid residue from a non-reducing terminal of ganglioside.

Abstract: The present invention provides a protein defined in the following (A) or (B), and DNA coding for the same:

Abstract: Sialidases localized on plasma membranes having the amino acid sequence of SEQ ID NO: 2 or SEQ ID NO: 4 and DNA coding for the sialidase having the nucleotide sequence of SEQ ID NO: 1 or SEQ ID NO: 3.